Three Hot Momentum Stocks to Consider in 2020

While 2020 could be rocky with the U.S. elections nearing, we’ve spotted some of the strongest stocks to own now that could double, if not triple your investment. One is likely to push higher on the coming mobile gaming boom. Another is rising on a potential augmented reality boom.

In addition, we’ve found a stock just starting to move thanks to a peanut allergy treatment.

Zynga Inc. (ZNGA)

ZNGA develops, markets, and operates social games as live services in the United States and internationally. The company’s games are played on mobile platforms, such as Apple iOS and Google’s Android operating systems, as well as on social networking sites, such as Facebook. It also provides advertising services comprising mobile and display ads, engagement ads and offers, and branded virtual items and sponsorships to advertising agencies and brokers; and licenses its own brands.

We believe the stock is setting up for another move higher.

Analysts at Stephens for example called the ZNGA stock the "best idea," adding, it's well-positioned for consolidation in the mobile gaming market," as quoted by Barron’s. "We believe the next 6 to 18 months will be a period of consolidation as established mobile players further leverage their core publishing infrastructure by acquiring sub-scale studios to drive growth. Zynga has a proven ability to successfully execute."

KeyBanc Capital has a price target of $8.50 with an overweight rating. “On a global basis, mobile is the largest and fastest growing segment of the gaming industry,” they note. “Gaming continues to take share of time spent on mobile phones and evolving technology and connectivity is enabling deeper and more quality games that monetize more effectively than ever before.”

In recent days, the company beat earnings expectations with a loss of $3.5 million, or breakeven per share, as compared to $559,000, or breakeven year over year. Analysts were looking for a
loss of three cents per share. Adjusted revenue came in at $433 million, as compared to analyst forecasts for $418 million.

ZNGA also forecast adjusted earnings of $350 million for 2020, as compared to expectations for $345.5 million. It's also forecasting adjusted revenue of $1.75 billion for the year, as compared to expectations for $1.74 billion.

**Himax Technologies Inc. (HIMX)**

HIMX is a fabless semiconductor company, they provide display imaging processing technologies in China, Taiwan, the Philippines, Korea, Japan, Europe, the United States, and internationally. The company operates through two segments, Driver IC and Non-Driver Products. It offers display driver integrated circuits (ICs) and timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation devices, and other consumer electronics devices. The company also designs and provides controllers for touch sensor displays; in-cell touch and display driver integration single-chip solutions; light-emitting diode driver and power management ICs; scaler products for monitors and projectors; tailor-made video processing IC solutions; silicon IPs; and liquid crystal on silicon micro-displays for augmented reality (AR) devices.

After swinging to a low of less than $2, it's recovered nicely to a recent high of $4.68. Analysts at Lake Street recently upgraded the stock from a hold to a buy with a price target of $5. One of the biggest reasons to like HIMX is its involvement with augmented reality, with Alphabet and Microsoft already using HIMX optical components for its AR. Better, according to Statista, the global augmented reality market could explode from $3.5 billion in 2017 to more than $198 billion in the next five years.

**Aimmune Therapeutics Inc. (AIMT)**

AIMT is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for the treatment of peanut and other food allergies. The stock has been incredibly explosive, running from a low of $19 in July 2019 to a recent price of $30.84. However, we
believe the stock could see higher highs after the U.S. FDA approved the company’s treatment for peanut allergies for those aged 4 through 17.

The company also said this is just the beginning, as it waits for approval in Europe, and for trial results among children between the ages of 1 and 4.